CROMSOURCE has been a trusted partner for European clients conducting work in the United States and Canada for over 15 years.
During that time our focus has been to build an expert and flexible infrastructure in North America providing comprehensive clinical research services to clients in Europe. From the provision of Regulatory Strategy consultancy and FDA/Health Canada representation to operational delivery of complex, multi-site projects involving medicines or medical devices, CROMSOURCE is a trusted partner. Our European clients benefit from our experience in the US and Canada, and appreciate that when their development plans include North America, the CROMSOURCE team will be there at every step, delivering expert regional support but from a European perspective.
“In the United States and Canada for over 15 years”
As a partner with a wide range of experience our clients rely on CROMSOURCE to flexibly and proactively support them with services carefully tailored to their needs. Whether this is the inclusion of a small number of North American sites in a multi-national project, or the delivery of a large multi-trial clinical development programme entirely in North America, CROMSOURCE has the experience to offer immediate benefits to our European clients.
Our work for European clients in the US and Canada has supported successful marketing applications with the FDA, and ranges from complex early phase studies in Oncology, Ophthalmology, and Rare Disease through pivotal studies involving large numbers of sites and patients in Respiratory, Oncology, Orthopaedics, Urology, Audiology, Rare Disease, and Central Nervous System Medicine.
Whatever the scope of service or nature of the request, CROMSOURCE keeps our European clients closely informed about the progress of their project in North America with the same ‘one team’ approach which lies at the heart of the CROMSOURCE global philosophy.
CROMSOURCE is a safe bridge across the Atlantic Ocean, and represents the ideal partner for European clients including North America in their clinical development plans.